Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Stöllberger, Claudia, Finsterer, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763635/
https://www.ncbi.nlm.nih.gov/pubmed/24288086
http://dx.doi.org/10.3390/ph5020155
_version_ 1782283049844604928
author Stöllberger, Claudia
Finsterer, Josef
author_facet Stöllberger, Claudia
Finsterer, Josef
author_sort Stöllberger, Claudia
collection PubMed
description Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
format Online
Article
Text
id pubmed-3763635
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37636352013-11-14 Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation Stöllberger, Claudia Finsterer, Josef Pharmaceuticals (Basel) Review Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran. MDPI 2012-02-03 /pmc/articles/PMC3763635/ /pubmed/24288086 http://dx.doi.org/10.3390/ph5020155 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Stöllberger, Claudia
Finsterer, Josef
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title_full Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title_fullStr Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title_full_unstemmed Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title_short Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
title_sort concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763635/
https://www.ncbi.nlm.nih.gov/pubmed/24288086
http://dx.doi.org/10.3390/ph5020155
work_keys_str_mv AT stollbergerclaudia concernsregardingtheuseofdabigatranforstrokepreventioninatrialfibrillation
AT finstererjosef concernsregardingtheuseofdabigatranforstrokepreventioninatrialfibrillation

Ejemplares similares